Cyclodextrin Therapy for Alzheimer’s Disease

News 1 March, 2018
CTD Holdings, Inc. has entered negotiations with Kerwin Research Center, LLC to explore the use of cyclodextrins (HPBCD) in the treatment of Alzheimer disease based on the success of HPBCD (it received orphan drug registration against Niemann Pick type C disease, called also childhood Alzheimer disease).
The principal investigator will be Diana Kerwin, MD, specialist in cognitive neurology and age-related neurodegenerative diseases. The clinical research program will be funded by an independent third party.